Research Library
Trevogrumab research
6 articles to explore, with links to 6 original sources.
New to this topic? Start with the Trevogrumab (REGN1033) guide.
About Trevogrumab
Trevogrumab, also designated REGN1033, is a monoclonal antibody investigated in myostatin-binding and Smad2/3 signaling research.
Understand the science
How researchers defined low lean mass at the start of COURAGE
Trevogrumab is a larger protein antibody that targets myostatin, a regulator of muscle mass. Investigators studied the antibody with semaglutide and examined whether the lean mass results differed in adults who entered the trial with low lean mass.
2 sources (2024, 2026)
What blocking two muscle signals changed in an early human trial
Trevogrumab is an investigational monoclonal antibody against myostatin, also known as GDF8. An older phase 1 trial investigated the effects of blocking myostatin and a second signal called activin A, separately and together. The trial had two parts.
2 sources (2024–2026)
Check methods and identity
What the COURAGE MRI substudy measured in the thigh
Trevogrumab is an investigational monoclonal antibody, a large protein engineered to block myostatin, also called GDF8. In 2026, the COURAGE trial sponsor reported an MRI substudy that asked whether adding this antibody to semaglutide changed thigh muscle volume.
3 sources (2024–2026)
How animal studies tested muscle and fat during weight change
Trevogrumab is an investigational monoclonal antibody that blocks myostatin. An older study in male mice and nonhuman primates examined what happened to lean tissue and fat when investigators blocked myostatin and activin A during treatment with a GLP-1 receptor agonist.
2 sources (2024–2026)
What an older sarcopenia trial measured with a body scan
Trevogrumab, also called REGN1033 in earlier studies, is a larger investigational antibody that blocks myostatin. An older randomized study in people with sarcopenia tested whether the antibody changed lean body mass over 12 weeks.
3 sources (2013–2026)
Interpret the evidence
Why COURAGE reported lean mass and weight separately at 52 weeks
Trevogrumab is a larger protein called a monoclonal antibody, designed to block the muscle growth regulator myostatin. The 2026 sponsor report from COURAGE compared changes on the scale with changes in whole-body lean mass when the investigational antibody was added to semaglutide.
2 sources (2024, 2026)
